Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astion Pharma Hand Cure is an over-the-counter (OTC) topical skincare product developed by Astion Pharma for the management of hand eczema. The formulation features the patented active ingredient Dermadexin®, a biolipid-niacin complex that acts as a film-forming agent. Upon application, it creates a thin, protective barrier over the skin, which helps to alleviate itching and supports the restoration of the skin's natural protective barrier. The product is intended for use on sore, red, scaly, and irritated skin and is formulated without corticosteroids. It has been clinically evaluated in randomized, double-blind, placebo-controlled trials and is indicated for adults and children over the age of two. Treatment is typically limited to 21 consecutive days, after which users are advised to transition to maintenance repair creams.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Astion Pharma Hand Cure.